Biosimilars | Current Treatment | Endocrinology | US/EU | 2017
Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator sector of the endocrinology market. Uptake of these products, as well as that of competing insulins and human growth hormone biologics including Omnitrope and Genotropin, will depend on the prescribing behavior of endocrinologists. For this reason, it is critical that manufacturers/marketers of insulin and somatropin biosimilars and brands understand which factors influence endocrinologists’ opinions, actions, and expectations. To this end, Decision Resources Group conducted primary market research with endocrinologists in France, Germany, and the United States.
Questions answered:
- Have endocrinologists received recommendations to use biosimilars?
- Are endocrinologists switching patients from reference brands to biosimilars?
- What factors do endocrinologists consider when choosing among competing biosimilars?
- How are insulin biosimilars and Omnitrope performing, and what are endocrinologists’ expectations for their future uptake?
- What are the key drivers and barriers to uptake of insulin and somatropin biosimilars?
Key markets covered:
- France
- Germany
- United States
Key companies mentioned:
- Boehringer Ingelheim
- Eli Lilly
- Merck & Co.
- Novo Nordisk
- Sanofi
Key drugs mentioned:
- Apidra
- Basaglar/Abasaglar
- Genotropin
- Humalog
- Humatrope
- Lantus
- Levemir
- Lusduna Nexvue/Lusduna
- Norditropin
- NovoLog/NovoRapid
- Nutropin
- Omnitrope
- Saizen
- Toujeo
- Tresiba
